Elan’s shareholders have given approval to the company’s acquisition by pharmaceutical firm Perrigo.
The $8.6 billion deal, which was announced in late July, will give the US drugs company control of Elan's royalty rights.
Perrigo will also create a new holding company in Ireland, which will also allow it to avail of the country's tax regime.
Elan investors holding more than two-thirds of the company's remaining shares were represented at the vote, according to the company, with more than 99.5% of them approving the deal.
The company said the deal remains subject to approval by the High Court, which is expected to be granted by the end of the year.
While issuing the company’s latest quarterly results, Perrigo’s CEO Joseph C Papa said he had hoped to finalise the deal by the end of 2013.
The acquisition ends a protracted battle between Elan and Royalty Pharma, which saw the latter make a number of hostile takeover bids for the Irish firm.
